补充维生素D对未控制支气管哮喘儿童FEV1%、FeNO及控制水平的影响

储卫红; 彭韶; 马莹莹; 张曼; 徐莉燕; 高艺伟; 高源; 苗雪艳

doi:10.16766/j.cnki.issn.1674-4152.002327

补充维生素D对未控制支气管哮喘儿童FEV1%、FeNO及控制水平的影响

doi: 10.16766/j.cnki.issn.1674-4152.002327

郑州大学第一附属医院儿科，河南郑州 450052

基金项目:

河南省高等学校重点科研项目 18A320013

详细信息

通讯作者:
彭韶，E-mail：summerrain0524@163.com

中图分类号: R725.6 R562.25
计量
- 文章访问数: 299
- HTML全文浏览量: 186
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-21
- 网络出版日期: 2022-03-04

Effect of vitamin D supplementation on FEV1%, FeNO and control level in children with uncontrolled bronchial asthma

Department of Paediatrics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China

摘要

摘要: 目的探讨补充维生素D(VD)对未控制哮喘儿童1秒钟用力呼气容积占预计值百分比(FEV1%)、呼出气一氧化氮(FeNO)及哮喘控制水平的影响。方法以2018年1月—2019年10月郑州大学第一附属医院儿童哮喘专科门诊就诊的131例未控制哮喘儿童为研究对象，采用抽签法简单随机分组方法分为观察组(71例)和对照组(60例)，观察组给予吸入性糖皮质激素+ β2受体激动剂+白三烯受体拮抗剂+VD，对照组未给予VD，其余治疗相同。随访3个月，每个月检测血清25羟维生素D(25 hydroxy vitamin D, 25OHD)、肺功能和FeNO，评估临床控制水平。结果 (1) FEV1%、FeNO在2组间、各时点间、组间和时间的交互作用差异均有统计学意义(F_FEV1%=9.545、600.842、12.018，F_FeNO=7.037、1 118.111、37.062，均P＜0.05)。(2)治疗第1、2、3个月，2组FEV1%差异有统计学意义(t_FEV1%=2.032、2.310、2.562，均P＜0.05)，观察组较对照组FEV1%上升快。(3)治疗第1、2、3个月，2组FeNO差异有统计学意义(t=-2.332、-5.940、-5.024，均P＜0.05)，观察组较对照组FeNO下降快。(4)治疗第2个月，观察组较对照组良好控制率高(51/20 vs.28/32，χ²=8.602，P=0.003)，第1、3个月2组间差异无统计学意义(均P＞0.05)。结论给予未控制哮喘儿童补充VD可能更快地提高FEV1%、降低FeNO，使哮喘控制提前。
- 维生素D /
- 支气管哮喘 /
- 儿童
Abstract: Objective To explore the effect of vitamin D (VD) supplementation on forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity (FEV1%), fractional exhaled nitric oxide (FeNO) and control level in children with uncontrolled asthma. Methods Children with uncontrolled asthma who visited the children's asthma clinic of the First Affiliated Hospital of Zhengzhou University from January 2018 to October 2019 were selected as study subjects and randomly divided into the observation and control groups. The observation group received inhaled glucocorticoid+β2 receptor agonist + leukotriene receptor antagonist+VD. The control group received the same treatment without VD. Serum 25 hydroxy vitamin D(25OHD), lung function and FeNO were tested, and clinical control level were evaluated at monthly follow-up for 3 months. Results (1) Statistical significance in FEV1% and FeNO was found between the two groups, between each time point and in interaction between group and time (F_FEV1%=9.545, 600.842, 12.018, F_FeNO=7.037, 1 118.111, 37.062, all P < 0.05). (2) At 1, 2 and 3 months of treatment, a significant difference in FEV1% was found between the two groups (t_FEV1%=2.032, 2.310, 2.562, all P < 0.05). FEV1% increased faster in the observation group than in the control group. (3) The difference was significant at 1, 2 and 3 months (t=-2.332, -5.940, -5.024, all P < 0.05) in FeNO between the two groups. FeNO decreased faster in the observation group than in the control group. (4) The good control rate of the observation group was higher than that of the control group in the second month of treatment (51/20 vs. 28/32, χ²=8.602, P=0.003). There was no significant difference between the two groups in the first and third months (all P>0.05). Conclusion VD supplementation in children with uncontrolled asthma may increase FEV1% and decrease FeNO quickly and allow asthma control in advance.
- Vitamin D /
- Bronchial asthma /
- Children

HTML全文

表 1 2组未控制哮喘儿童不同时间血清VD比较(x±s，ng/mL)

组别	例数	基础水平	第1个月	第2个月	第3个月	F值	P值
观察组	71	16.41±2.64	24.35±2.84^a	30.50±2.45^ab	36.39±3.58^abc	1 202.060	＜0.001
对照组	60	15.87±1.54	15.41±1.58	16.09±1.91	15.68±1.41	1.899	0.136
t值		1.153	17.691	30.217	34.345
P值		0.252	＜0.001	＜0.001	＜0.001
注：与基础水平比较，^aP＜0.05；与第1个月比较，^bP＜0.05；与第2个月比较，^cP＜0.05。

下载: 导出CSV

表 2 2组未控制哮喘儿童不同时间FEV1%比较(x±s)

组别	例数	基础水平	第1个月	第2个月	第3个月	F值	P值
观察组	71	65.23±8.66	74.36±8.42^a	82.70±7.00^ab	89.85±7.61^abc	255.685	＜0.001
对照组	60	67.00±9.76	70.70±8.33^a	77.20±6.72^ab	83.55±7.22^abc	131.733	＜0.001
t值		1.131	2.032	2.310	2.562
P值		0.261	0.045	0.023	0.012
注：与基础水平比较，^aP < 0.05；与第1个月比较，^bP < 0.05；与第2个月比较，^cP < 0.05。

下载: 导出CSV

表 3 2组未控制哮喘儿童不同时间FeNO比较(x±s，ppb)

组别	例数	基础水平	第1个月	第2个月	第3个月	F值	P值
观察组	71	40.77±5.87	30.89±4.42^a	19.21±4.15^ab	17.00±2.83^abc	480.665	＜0.001
对照组	60	39.18±6.19	33.00±5.72^a	25.46±5.59^ab	20.50±3.60^abc	212.728	＜0.001
t值		1.162	-2.332	-5.940	-5.024
P值		0.249	0.022	＜0.001	＜0.001
注：与基础水平比较，^aP < 0.05；与第1个月比较，^bP < 0.05；与第2个月比较，^cP < 0.05。

下载: 导出CSV

表 4 2组未控制哮喘儿童不同时间哮喘控制情况比较[例(%)]

组别	例数	第1个月		第2个月		第3个月
组别	例数	良好控制	部分控制+未控制	良好控制	部分控制+未控制	良好控制	部分控制+未控制
观察组	71	19(26.8)	52(73.2)	51(71.8)	20(28.2)	62(87.3)	9(12.7)
对照组	60	14(23.3)	46(76.7)	28(46.7)	32(53.3)	48(80.0)	12(20.0)
χ²值		0.203		8.602		1.296
P值		0.653		0.003		0.255

下载: 导出CSV

参考文献(18)

[1]	中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童支气管哮喘诊断与防治指南(2016年版)[J]. 中华儿科杂志, 2016, 54(3): 167-181. doi: 10.3760/cma.j.issn.0578-1310.2016.03.003
[2]	DIXON A E, HOLGUIN F. Diet and metabolism in the evolution of asthma and obesity[J]. Clin Chest Med, 2019, 40(1): 97-106. doi: 10.1016/j.ccm.2018.10.007
[3]	PFEFFER P E, HAWRYLOWICZ C M. Vitamin D in asthma: Mechanisms of action and considerations for clinical trials[J]. Chest, 2018, 153(5): 1229-1239. doi: 10.1016/j.chest.2017.09.005
[4]	OZKARS M Y, KESKIN O, ALMACIOGLU M, et al. The relationship between serum vitamin D level and asthma[J]. North Clin Istanb, 2019, 6(4): 334-340.
[5]	JOLLIFFE D A, GREENBERG L, HOOPER R L, et al. Vitamin D supplementation to prevent asthma exacerbations: A systematic review and meta-analysis of individual participant data[J]. Lancet Respir Med, 2017, 5(11): 881-890. doi: 10.1016/S2213-2600(17)30306-5
[6]	HANANIA N A, MASSANARI M, JAIN N, et al. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions[J]. Ann Allergy Asthma Immunol, 2018, 120(4): 414-418. doi: 10.1016/j.anai.2018.01.031
[7]	张明, 邱蕾, 贺玉霜, 等. 潍坊地区5 132例6岁以下儿童维生素D水平调查及相关危险因素分析[J]. 中华全科医学, 2020, 18(5): 779-782. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202005022.htm
[8]	HOLLAMS E M, TEO S M, KUSEL M, et al. Vitamin D over the first decade and susceptibility to childhood allergy and asthma[J]. J Allergy Clin Immunol, 2017, 139(2): 472-481. doi: 10.1016/j.jaci.2016.07.032
[9]	LITONJUA A A. Vitamin D and childhood asthma: Causation and contribution to disease activity[J]. Curr Opin Allergy Clin Immunol, 2019, 19(2): 126-131. doi: 10.1097/ACI.0000000000000509
[10]	LIU J, DONG Y Q, YIN J, et al. Meta-analysis of vitamin D and lung function in patients with asthma[J]. Respir Res, 2019, 20(1): 161. doi: 10.1186/s12931-019-1072-4
[11]	沈佩芳, 田军, 丁晓玲. 血清维生素D水平与支气管哮喘患儿病情严重程度的相关性[J]. 浙江临床医学, 2018, 20(7): 1190-1192. https://www.cnki.com.cn/Article/CJFDTOTAL-JTYY201504012.htm
[12]	张译, 王冲, 刘靖雷. 支气管哮喘儿童血清维生素D水平与肺功能相关性研究进展[J]. 海南医学, 2020, 31(17): 2265-2268. doi: 10.3969/j.issn.1003-6350.2020.17.026
[13]	BABAR M Z M, HUSSAIN M, MAJEED S A. Vitamin D supplementation improves FEV1 in patients of bronchial asthma[J]. Pak J Med Sci, 2017, 33(5): 1144-1147.
[14]	TACHIMOTO H, MEZAWA H, SEGAWA T, et al. Improved control of childhood asthma with low-dose, short-term vitamin D supplementation: A randomized, double-blind, placebo-controlled trial[J]. Allergy, 2016, 71(7): 1001-1009. doi: 10.1111/all.12856
[15]	JARTTI T, BØNNELYKKE K, ELENIUS V, et al. Role of viruses in asthma[J]. Semin Immunopathol, 2020, 42(1): 61-74. doi: 10.1007/s00281-020-00781-5
[16]	MARTINEAU A R, JOLLIFFE D A, HOOPER R L, et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data[J]. BMJ, 2017, 356: i6583. DOI: 1a1136/bmj.16583.
[17]	闫玉晓, 李宇宁. 激素抵抗型哮喘发病机制和维生素D对其部分机制的影响[J]. 中国当代儿科杂志, 2019, 21(7): 724-729. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ201907022.htm
[18]	PFEFFER P E, LU H, MANN E H, et al. Effects of vitamin D on inflammatory and oxidative stress responses of human bronchial epithelial cells exposed to particulate matter[J]. PLoS One, 2018, 13(8): e0200040. DOI: 10.1371/journal.pone.0200040.